Notice of Interim Results and Webcast
GUILDFORD, SURREY / ACCESSWIRE / August 15, 2023 / ANGLE plc (AIM:AGL), (OTCQX:ANPCY), a world-leading liquid biopsy company with innovative CTC diagnostic solutions for the research and diagnostic oncology market, will be releasing its interim results for the six months ended 30 June 2023 on Thursday 7 September 2023.
A meeting for analysts will be held at 11:00 am BST on Thursday 7 September 2023 at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London EC1A 4HD.
A live webcast of the analyst meeting can be accessed via ANGLE’s Investor Centre page, https://angleplc.com/investor-relations/corporate-presentations/, with Q&A participation reserved for analysts only. Please register in advance and log on to the webcast approximately 5 minutes before 11:00 am on the day of the results. A recording of the webcast will be made available on ANGLE’s website following the results meeting.
For further information:
|
ANGLE plc |
+44 (0) 1483 343434 |
|
Andrew Newland, Chief Executive |
|
|
Berenberg (NOMAD and Joint Broker) |
+44 (0) 20 3207 7800 |
|
Jefferies (Joint Broker) |
+44 (0) 20 7029 8000 |
|
FTI Consulting |
+44 (0) 203 727 1000 |
For Frequently Used Terms, please see the Company’s website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative CTC diagnostic solutions for the research and diagnostic oncology market using a simple blood sample. ANGLE’s FDA cleared and patent protected circulating tumor cell (CTC) harvesting technology known as the Parsortix® system enables complete analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE’s commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system and associated consumables. The clinical services business is offered through ANGLE’s GCP-compliant laboratories in the UK and the United States. Services include custom made assay development and clinical trial testing for pharma.
Over 80 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: ANGLE plc
View source version on accesswire.com:
https://www.accesswire.com/774207/Angle-Notice-of-Interim-Results
Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers…
CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…
Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…
MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…
Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…